SarQoL Questionnaire in Community-Dwelling Older Adults under EWGSOP2 Sarcopenia Diagnosis Algorithm: A New Screening Method?

Guillamón-Escudero, Carlos; Diago-Galmés, Angela; Zuazua-Rico, David; Maestro-González, Alba; Tenias, Jose María; Castillo, José Miguel Soriano del; Fernández-Garrido, Julio

doi:10.3390/ijerph19148473

Cited by 10 publications

(14 citation statements)

References 63 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference may be due to the fact that the prevalence estimate was obtained from just two studies of those included in the meta-analysis [ 39 ]. Furthermore, there may be possible variations by race, age, or study setting, as similar figures are observed in similar populations [ 18 ].…”

Section: Discussionmentioning

confidence: 93%

“…The application of the sarcopenia assessment algorithm, based on the EWGSOP2 criteria, and the sarcopenic obesity algorithm, based on the EASO/ESPEN criteria, is relatively time-consuming and resource-intensive, underscoring the need for more abbreviated screening instruments such as the Sarc-F or the Mini Sarcopenia Risk Assessment (MSRA). Health-related quality of life could also be used for screening, and since a specific QoL questionnaire (SarQol) became available, several cutoff points have been proposed, from ≤ 52.4 points [ 17 ] to ≤ 60 points [ 18 ]. These thresholds could be useful for screening older people with sarcopenia, providing an acceptable screening accuracy in relation to Sarc-F. That said, confirming the cutoffs with other population cohorts is still necessary [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

“…A recent validation study of the SarQol in Spanish showed good metric properties [ 19 ], and a cutoff of ≤ 60 points has been proposed in the Spanish population [ 18 ]. Given the need to confirm these cutoffs in women with sarcopenic obesity, the primary aim of this study is to compare quality of life in older women without sarcopenia, with sarcopenia, and with sarcopenic obesity, and to measure the SarQoL’s metric properties in order to establish a cutoff in QoL assessments that could be used in the diagnostic pathways for these conditions in community-dwelling older women.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Fonfría-Vivas¹,

Pérez‐Ros²,

Barrachina-Igual³

et al. 2023

Aging Clin Exp Res

View full text Add to dashboard Cite

Background Health-related quality of life (HRQoL) may be impaired in the presence of sarcopenia. Since a specific quality of life questionnaire became available for sarcopenia (SarQol), cutoffs to screen for this condition have been proposed, prompting the need to assess them in different populations. Due to the lack of consensus on diagnostic criteria, the tool has not yet been analyzed in screening for sarcopenic obesity. Aim Our aim is to measure the SarQoL’s metric properties and establish a cutoff in QoL assessments that could be used along the diagnostic pathway for sarcopenia and sarcopenic obesity in community-dwelling older women. Methods This cross-sectional study assessed women aged ≥ 70 years using the SarQol, sarcopenia criteria (EWGSOP2) and sarcopenic obesity criteria (ESPEN/EASO). Cutoffs for the SarQol were defined with a receiver-operating characteristics (ROC) curve, and sensitivity and specificity were analyzed. Results Of the 95 included women (mean age 76.0 years, standard deviation [SD] 5.7), 7.3% (n = 7) were classified as having sarcopenic obesity, 22.1% (n = 21) as having sarcopenia, and 70.5% (n = 67) as not having sarcopenia. The total SarQol score was higher in women without sarcopenia (66.5 SD 16.2) versus those with sarcopenia (56.6 SD 15.6) and sarcopenic obesity (45.1 SD 7.9). A cutoff of ≤ 60 points is proposed for sarcopenia screening (area under the ROC curve [AUC] 0.67; 95% confidence interval [CI] 0.53–0.80; sensitivity 61.9%; specificity 62%), and ≤ 50 points for sarcopenic obesity (AUC 0.85; 95% CI 0.74–0.95; sensitivity 71.4%; specificity 76.9%). Conclusions Quality of life is compromised in women with sarcopenia and especially in those with sarcopenic obesity. The SarQol could be useful in screening for these conditions, providing insight into health-related quality of life in older people with sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Fonfría-Vivas¹,

Pérez‐Ros²,

Barrachina-Igual³

et al. 2023

Aging Clin Exp Res

View full text Add to dashboard Cite

show abstract

“…The list of excluded studies and their respective reasons of exclusion is available on our Open Science Framework deposit (https://osf.io/rqhvy/). Therefore, a total of 43 observational studies were included in this systematic review, 42 cross‐sectional studies 5,27–67 and one prospective study 68 for which baseline values of HRQoL for the sarcopenic and non‐sarcopenic groups were used (Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Sarcopenia and health‐related quality of life: A systematic review and meta‐analysis

Beaudart

Demonceau

Reginster

et al. 2023

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

The decrease of physical abilities and functional decline that can be caused by musculoskeletal conditions such as sarcopenia, can lead to higher levels of dependency and disability. Therefore, it may influence patient reported outcome measures (PROM), such as the health‐related quality of life (HRQoL). The purpose of this systematic review and meta‐analysis is to provide a comprehensive overview of the relationship between sarcopenia and HRQoL. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) were followed throughout the whole process of this work. A protocol was previously published on PROSPERO. The electronic databases MEDLINE, Scopus, Allied and Complementary Medicine (AMED), EMB Review – ACP Journal Club, EBM Review ‐ Cochrane Central of Register of Controlled Trials and APA PsychInfo were searched until October 2022 for observational studies reporting a HRQoL assessment in both sarcopenic and non‐sarcopenic individuals. Study selection and data extraction were carried out by two independent researchers. Meta‐analysis was performed using a random effect model, reporting an overall standardized mean difference (SMD) and its 95% confidence interval (CI) between sarcopenic and non‐sarcopenic individuals. Study quality was measured using the Newcastle‐Ottawa Scale and the strength of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. The search strategy identified 3725 references from which 43 observational studies were eligible and included in this meta‐synthesis study. A significantly lower HRQoL was observed for sarcopenic individuals compared with non‐sarcopenic ones (SMD −0.76; 95% CI −0.95; −0.57). Significant heterogeneity was associated with the model (I2 = 93%, Q test P‐value <0.01). Subgroup analysis showed a higher effect size when using the specific questionnaire SarQoL compared with generic questionnaires (SMD −1.09; 95% CI −1.44; −0.74 with the SarQoL versus −0.49; 95% CI −0.63; −0.36 with generic tools; P‐value for interaction <0.01). A greater difference of HRQoL between sarcopenic and non‐sarcopenic was found for individuals residing in care homes compared with community‐dwelling individuals (P‐value for interaction <0.001). No differences were found between age groups, diagnostic techniques, and continents/regions. The level of evidence was rated as moderate using the GRADE assessment. This systematic review and meta‐analysis combining 43 observational studies shows that HRQoL is significantly reduced in sarcopenic patients. The use of disease‐specific HRQoL instruments may better discriminate sarcopenic patients with respect to their quality of life.

show abstract

“…Recently, a study suggested a correlation between the SarQoL score and the risk level of suffering sarcopenia [51]. 60 points was the cut-off between high and moderate risk of sarcopenia.…”

Section: Discussionmentioning

confidence: 99%

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: an observational trial (SARA-OBS)

Fielding,

Rolland,

Bruyere

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Aging is associated with a progressive change of body composition characterized by muscle mass decline and accumulation of adipose tissue that can lead to sarcopenia and obesity, respectively. The prevalence of sarcopenia is poorly known given the different parameters and thresholds in proposed definitions. The combination of obesity (defined as a percentage of body fat mass of >25% in men and >35% in women) and sarcopenia (SO) adds complexity to the characterization of this pathology. SARA-OBS aimed to better characterize sarcopenia (including SO) and its consequences on physical function over time, in community-dwelling older adults at risk of mobility disability, and to support the design of further interventional clinical trials. Methods This was an international, multicenter, 6-month observational study of men and women aged ≥65 years suffering from sarcopenia according to the Foundation for the National Institute of Health (FNIH) cut-offs for Sarcopenia and with a Short Physical Performance Battery (SPPB) ≤ 8. The primary endpoint was the change in Gait Speed (GS) in the 400-meter walking test (400MWT), reported at baseline and at Month 6/ end of the study (EOS). Secondary endpoints included changes in handgrip strength (HGS), physical performance (6-Minute Walking Distance [6MWD], SPPB), the Physical Function Domain (PF-10) sub-score and total score of the SF-36 survey and the Sarcopenia and Quality of Life (SarQoL) questionnaire. Results Overall, the mean (±SD) change from baseline to Month 6/EOS in 400MWT GS was -0.027±0.171 m/sec (p=0.064). Both GS and 6MWD decreased significantly in subgroup with GS ≥ 0.8 m/sec at baseline (‑0.047±0.185 m/sec; p=0.017 and -24.01±68.24 m; p=0.001, respectively). In subgroup with SPPB = 8 at baseline, 6MWD also decreased (-36.80±67.60 m; p<0.001). We observed a significant change from baseline for 6MWD in the SO subgroup (‑18.30±81.95 m; p=0.013). Neither HGS nor SarQoL changed significantly from baseline to Month 6/EOS. Conclusions SARA-OBS results contribute to define subgroups of older adults at risk of functional decline over 6 months, specifically subjects with SPPB = 8, affecting GS and the 6MWD. Additionally, the SO subpopulation exhibited a relevant deterioration in physical function as evaluated by the 6MWD. Trial registration: NCT03021798 (ClinicalTrials.gov). Date of registration: 16/01/2017

show abstract

SarQoL Questionnaire in Community-Dwelling Older Adults under EWGSOP2 Sarcopenia Diagnosis Algorithm: A New Screening Method?

Cited by 10 publications

References 63 publications

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Sarcopenia and health‐related quality of life: A systematic review and meta‐analysis

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: an observational trial (SARA-OBS)

Contact Info

Product

Resources

About